As shown in Figure 1, this structured review evaluated these 133 articles to comprehensively cover the topic of PSMA-labeled radiopharmaceuticals with radioisotopes, particularly for prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.